Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Eupatorium perfoliatum 30 C: Eupatorium perfoliatum 30 C twice Daily for 5 consecutive days in empty stomach orally. One adult dose is 4 globules of no. 20 medicated globule. One child
Sponsors
Ministry of AYUSH
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects testing positive for SARS CoV-2 by RT-PCR, presenting with no symptoms or mild symptoms. 2. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study.
Exclusion criteria
Exclusion criteria: 1. Cases of COVID-19 with clinical severity ranging from moderate to critical. 2. Pregnant and lactating females. 3. Subjects having uncontrolled and unstable co morbidity. 4. Immunocompromised subjects or those taking any kind of immunosupressive therapy. 5. COVIC-19 positive cases participating as subjects in other COVID-19 clinical trails. 6. Subjects having past history of allergy to any medicine that is part of the Homoeopathic intervention. Other conditions, which in the opinion of the investigator, makes the patient unsuitable for enrollment or could interfere with his participation in, and completion of the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effectiveness of Homoeopathic medicine Eupatorium perfoliatum 30 C in preventing the progression of severity of the disease in the SARS-Cov-2 tested positive asymptomatic and mild cases of COVID-19.Timepoint: 3 month | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess the changes in Quality of Life (QoL) of the subjects using WHO QOL-BREF scale. 2. To assess the safety of Eupatorium perfoliatum 30 C drug by observing for adverse events.Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr Tapan Nath
North Eastern Institute of Ayurveda and Homoeopathy (NEIAH)
Outcome results
None listed